Core Insights - Corcept Therapeutics is a mid-cap biotechnology company focused on therapies for severe endocrine and oncologic conditions, leveraging cortisol modulation to meet unmet medical needs with a growing portfolio of proprietary drug candidates [1] - The company generates revenue primarily from Korlym, an FDA-approved therapy for Cushing's syndrome, and is advancing a pipeline of selective cortisol modulators targeting various disorders [2] Transaction Details - William Guyer, the chief development officer, exercised 20,000 stock options and sold the resulting shares for approximately $703,656, which reflects a significant transaction involving direct common stock holdings [4] - Following this transaction, Guyer's direct common stock holdings decreased from 21,235 shares to 1,235 shares, a reduction of 94.18%, although he retains stock options for 250,000 shares [3] Financial Performance - Corcept reported third-quarter revenue of $207.6 million, an increase from $182.5 million year-over-year, driven by growth in Korlym prescriptions [6] - The company reaffirmed its full-year revenue guidance of $800 million to $850 million and ended the quarter with $524 million in cash and investments, indicating strong balance sheet flexibility [6] Market Context - The stock experienced a sharp decline on December 31 following an FDA complete response letter for relacorilant; however, the transaction by Guyer is viewed as a portfolio management decision rather than a shift in long-term outlook [5][7] - The core business remains strong despite regulatory setbacks, with the focus on clinical execution and the future of relacorilant being more critical than the recent stock transaction [7]

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On January 2, Canaccord Genuity cut its price target on Corcept Therapeutics Incorporated (NASDAQ:CORT) from $140 to $99 but kept its Buy rating on the stock. This adjustment comes after the company reported that the FDA issued a Complete Response Letter regarding the New Drug Application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism ...

Company Overview - Corcept Therapeutics is a commercial-stage biotech company focused on treatments for cortisol modulation, particularly related to Cushing's Syndrome [1] Product Information - Since 2012, the company has marketed Korlym as a treatment for Cushing's Syndrome [1]

Core Insights - Corcept Therapeutics (CORT) received a complete response letter (CRL) from the FDA regarding its new drug application (NDA) for relacorilant, a selective cortisol modulator intended for treating hypercortisolism (Cushing's syndrome) [1][5] - Following the announcement, Corcept's shares fell by 50.4% on December 31, 2025 [1][5] - The FDA's decision was based on the need for additional evidence of relacorilant's effectiveness, despite positive results from the GRACE and GRADIENT studies [3][5] Regulatory Developments - The NDA for relacorilant was submitted in December 2024, with an expected decision date of December 30, 2025 [2] - The FDA indicated that further studies are required to establish the drug's effectiveness for patients with hypertension secondary to hypercortisolism, which may delay approval [4] Financial Impact - Over the past six months, Corcept's shares have decreased by 51.8%, contrasting with a 3.4% increase in the industry [4] - Korlym, Corcept's currently marketed drug for Cushing's syndrome, generated sales of $559.3 million in the first nine months of 2025, reflecting a year-over-year increase of approximately 13.4% [9] Future Prospects - Corcept is also pursuing relacorilant for other indications, including a combination therapy for platinum-resistant ovarian cancer, with regulatory decisions expected in 2026 [6][7] - The outcome of the FDA's CRL for relacorilant in Cushing's syndrome may influence the upcoming decision regarding its use in ovarian cancer [9]

Corcept Therapeutics (CORT) crashed on Dec. 31 after the Food and Drug Administration (FDA) rejected its application for relacorilant, its investigational treatment for Cushing’s syndrome. The agency’s Complete Response Letter cited insufficient data for conducting a favorable benefit-risk assessment, requiring additional evidence of effectiveness for the hypertension treatment in patients with hypercortisolism. More News from Barchart Following the nosedive on Wednesday, CORT stock is down some 70% ve ...

Core Insights - Corcept Therapeutics experienced a significant stock decline of approximately 50% on December 31 due to the FDA's request for additional data on relacorilant, its treatment for Cushing's syndrome, raising concerns about the company's pipeline strength [1][2] - The setback has led analysts to remove relacorilant from financial models, negatively impacting investor confidence and future revenue expectations [2][3] - Despite the negative news, some analysts believe the market reaction may be exaggerated, suggesting potential upside for the stock if management can address regulatory concerns [4][6] Financial Performance - In the latest reported quarter, Corcept generated nearly $20 million in net income and $208 million in revenue, reflecting a year-over-year increase of approximately 14% [7] - The company's price-to-sales (P/S) ratio is around 10, which is considered reasonable for a fast-growing biotech firm [5] Market Position and Future Outlook - Korlym, Corcept's existing product, is facing pressure from generic competition, particularly from Teva Pharmaceuticals, limiting growth potential in its primary therapeutic area [3] - The ongoing research in ovarian cancer and the potential of relacorilant in oncology could provide new revenue streams, indicating that the company is not fundamentally broken despite recent setbacks [8][9] - The current valuation may present an attractive entry point for long-term investors, especially if the company can successfully navigate regulatory challenges and diversify its pipeline [8]

Core Insights - Corcept Therapeutics' Relacorilant is under FDA review with a PDUFA target date of December 30, 2025, which is crucial for the company's financial strategy to diversify revenue sources beyond Korlym [1] - The outcome of the PDUFA review is critical, as an unfavorable result could significantly impact Corcept's valuation due to the lack of other pre-registration drugs expected to reach approval in the next 3-5 years [1] Clinical & Regulatory Assessment - Relacorilant is a selective glucocorticoid receptor antagonist aimed at managing hypercortisolism in endogenous Cushing's syndrome, with its NDA supported by data from two Phase 3 trials: GRACE and GRADIENT [2] - In the GRACE trial, relacorilant met its primary endpoint, showing that patients switching to placebo had a higher risk of losing hypertension control, while in the GRADIENT trial, it failed to meet its primary endpoint of reducing mean systolic blood pressure [3] - The efficacy of relacorilant may be more pronounced in patients with non-adrenal etiology of endogenous Cushing's syndrome, which constitutes the majority of cases, but the failure in the GRADIENT trial raises concerns about the NDA's approval likelihood [3] Financial Position Outlook - Corcept Therapeutics has a market capitalization of $8.9 billion and maintains a strong liquidity position with no long-term debt, indicating financial stability [4] - The increase in R&D and SG&A expenses is consistent with the company's expanding clinical activities and preparations for the Relacorilant PDUFA event, and is not viewed as alarming [4] - The company's share outstanding remains stable with no imminent dilution expected, largely due to increased revenue from the commercialization of Korlym, which supports pipeline development [5]

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best biotech stocks to buy according to Wall Street analysts. On November 25, H.C. Wainwright reiterated a Buy rating and a $145 price target on the stock, citing its strong growth prospects despite commercial challenges. Wall Street Firms Tout Corcept Therapeutics Incorporated (CORT) Prospects on Korlym Medication Prospects The research firm has reiterated its confidence in the company’s Korlym medication, whose sales are projected to grow by ...

Core Insights - The article emphasizes the emergence of new investment opportunities in stocks with improving fundamentals and undervalued potential, as investors often regret not buying these stocks sooner [1][3] - Morgan Stanley has raised its 12-month S&P 500 target to 7,800, driven by a reversal in negative policy and earnings expectations, indicating a bullish outlook for the market [1][2] - The article presents a list of 11 stocks that are considered strong investment opportunities based on their competitive positions, consistent returns, and exposure to long-term trends [3] Market Outlook - Recent policy actions have been more constructive than anticipated, with a supportive Federal Reserve stance acting as a tailwind for positive earnings revisions [2] - The tech sector is expected to continue strong performance, with forecasts of around 20% returns by 2026, particularly for AI-related stocks [2] Stock Selection Methodology - The selection process involved screening U.S.-listed companies with a market capitalization over $2 billion and total returns of at least 50% over the past three years [6] - The final list was narrowed down to companies with a five-year average return on equity above 20% and a free cash flow margin exceeding 20%, with a minimum upside potential of 15%-20% [6] Hedge Fund Interest - The article highlights the significance of stocks that hedge funds are investing in, as research indicates that imitating top hedge fund picks can lead to market outperformance [7] Featured Stocks - Corcept Therapeutics Incorporated (NASDAQ:CORT) has a price return of 261.8% over three years, a return on equity of 23.3%, and a potential upside of 62.4% [8] - InterDigital Inc. (NASDAQ:IDCC) has a price return of 608.1% over three years, a return on equity of 24.3%, and a potential upside of 28.3% [14] - AppFolio Inc. (NASDAQ:APPF) has a price return of 103.2% over three years, a return on equity of 20.6%, and a potential upside of 37.9% [20]

It has been about a month since the last earnings report for Corcept Therapeutics (CORT) . Shares have added about 9.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Corcept due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.Corcept Q3 Earnings & Revenues Lag Estima ...